Tech Company Financing Transactions

Macrolide Pharmaceuticals Funding Round

Macrolide Pharmaceuticals, operating out of Watertown, scored $20 million from Advent Life Sciences, Gurnet Point Capital and Novartis Venture Fund.

Transaction Overview

Company Name
Macrolide Pharmaceuticals
Announced On
4/3/2018
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Undisclosed
Investors

Advent Life Sciences (Lead Investor)

Gurnet Point Capital (Lead Investor)

Novartis Venture Fund (Lead Investor)

Roche Venture Fund (Lead Investor)

SR One Capital Management (Lead Investor)

Proceeds Purpose
The new funding from both the financing and previously announced CARB-X award will accelerate development of the company's novel, IV and orally available macrolide antibiotics to address serious infections, including work to support filing an Investigational New Drug (IND) application for its lead program that addresses a significant unmet clinical need for antibiotics to treat infections caused by resistant Gram-negative pathogens.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
480 Arsenal St. 130
Watertown, MA 02472
USA
Phone
(617) 453-9091
Website
www.macrolidepharma.com
Email Address
[email protected]
Overview
Macrolide Pharmaceuticals, LLC. is a new anti-infective company founded to advance groundbreaking technology developed by Professor Andrew Myers of Harvard University.
Profile
Macrolide Pharmaceuticals LinkedIn Company Profile
Social Media
Macrolide Pharmaceuticals Company Twitter Account
Company News
Macrolide Pharmaceuticals News
Facebook
Macrolide Pharmaceuticals on Facebook
YouTube
Macrolide Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Mahesh Karande
  Mahesh Karande LinkedIn Profile  Mahesh Karande Twitter Account  Mahesh Karande News  Mahesh Karande on Facebook
Chief Financial Officer
Andrew Littlehale
  Andrew Littlehale LinkedIn Profile  Andrew Littlehale Twitter Account  Andrew Littlehale News  Andrew Littlehale on Facebook
Vice President
Richard Alm
  Richard Alm LinkedIn Profile  Richard Alm Twitter Account  Richard Alm News  Richard Alm on Facebook
Vice President
Roger Clark
  Roger Clark LinkedIn Profile  Roger Clark Twitter Account  Roger Clark News  Roger Clark on Facebook
VP - Engineering
Yoshitaka Ichikawa
  Yoshitaka Ichikawa LinkedIn Profile  Yoshitaka Ichikawa Twitter Account  Yoshitaka Ichikawa News  Yoshitaka Ichikawa on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/3/2018: Twist Bioscience venture capital transaction
Next: 4/3/2018: MetricStory venture capital transaction

 

Share this article

 

Where The Data Comes From

Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.